

Vaccine Updates

2/2/22

FDA Approval of Second COVID-19 Vaccine: Moderna

- FDA-approved vaccines have undergone standard process for reviewing quality, safety and effectiveness included in Biologics License Application (full licensure).
- The approved Moderna vaccine will be marketed as Spikevax, for the prevention of COVID-19 in individuals \geq 18 years of age.
- Spikevax has the same formulation as and can be used interchangeably with the EUA Moderna COVID-19 Vaccine.
- Moderna vaccine has been available under emergency use authorization (EUA) since December 2020.

FDA Approval of Second COVID-19 Vaccine: Moderna

- Effectiveness (analyses before emergence of Omicron)
 - 93% VE against COVID-19 infection
 - 98% VE against severe disease
- Safety
 - Increased risks for myocarditis particularly within 7 days after 2nd dose of vaccine in males 18 – 24 years of age. Majority of cases had resolution of symptoms but some required ICU.
 - Ongoing studies evaluating long-term outcomes of myocarditis and pregnancy registry study.

Next ACIP meeting 2/4/22

- February 4, 2022
- 10:00am – 5:00pm ET
- Virtual meeting, no registration required
- Webcast link and future agenda (not yet posted) available at www.cdc.gov/vaccines/acip/index.html

Confirmed COVID-19 Cases among Residents and Rate per 1,000 Resident-Weeks in Nursing Homes, by Week—United States


Display by State

CA

Display by FEMA/HHS Region

All

Cases Deaths



* Data are likely accruing, all data can be modified from week-to-week by facilities

For the purpose of creating this time-series graph, data that fail certain quality checks or appear inconsistent with surveillance protocols are assigned a value based on their patterns for data-entry or excluded from analysis

Data source: Centers for Disease Control and Prevention, National Healthcare Safety Network

For more information: <https://www.cdc.gov/nhsn/lite/covid19/index.html>

Accessibility: [Right click on the graph area to show as table]

Data as of 1/31/2022 5:30 AM


Display by State

CA

Display by FEMA/HHS Region

All

Cases Deaths



* Data are likely accruing, all data can be modified from week-to-week by facilities

For the purpose of creating this time-series graph, data that fail certain quality checks or appear inconsistent with surveillance protocols are assigned a value based on their patterns for data-entry or excluded from analysis

Data source: Centers for Disease Control and Prevention, National Healthcare Safety Network

For more information: <https://www.cdc.gov/nhsn/ltr/covid19/index.html>

Accessibility: [Right click on the graph area to show as table]


Data as of 1/31/2022 5:30 AM

Booster doses in CA

Vaccinated Status by Group

Select Category: Age
Select County: Statewide
Select Primary Series vs Booster: Booster Status

Booster status by age





Percentage of Residents in Nursing Homes with Complete COVID-19 Vaccination Receiving Additional Primary or Booster Dose, by Week – United States




Complete Vaccination: The percentage of residents who received all doses required to be fully vaccinated. **Additional primary or booster dose:** An additional dose refers to a subsequent dose of vaccine administered to people who likely did not mount a protective immune response after initial vaccination. A booster dose refers to a subsequent dose of vaccine administered to enhance or restore protection by the primary vaccination which might have waned over time.

Select By State

CA
▼

Select By Region

All
▼



For weeks ending 8/29-9/26, facilities reporting 100% of fully vaccinated individuals received an additional primary or booster dose were excluded. Data for the most recent week are still accruing.
 Data source: Centers for Disease Control and Prevention, National Healthcare Safety Network: Accessibility: [Right click on the graph area to show as table]
 For more information: <https://www.cdc.gov/nhsn/ltc/weekly-covid-vac/index.html>

Data as of 1/24/2022 5:30 AM

Percentage of Staff in Nursing Homes with Complete COVID-19 Vaccination Receiving Additional Primary or Booster Dose, by Week – United States


Complete Vaccination: The percentage of staff who received all doses required to be fully vaccinated. **Additional primary or booster dose:** An additional dose refers to a subsequent dose of vaccine administered to people who likely did not mount a protective immune response after initial vaccination. A booster dose refers to a subsequent dose of vaccine administered to enhance or restore protection by the primary vaccination which might have waned over time.

Select By State

CA
▼

Select By Region

All
▼



For weeks ending 8/29-9/26, facilities reporting 100% of fully vaccinated individuals received an additional primary or booster dose were excluded. Data for the most recent week are still accruing.

Data source: Centers for Disease Control and Prevention, National Healthcare Safety Network: Accessibility: [Right click on the graph area to show as table]

For more information: <https://www.cdc.gov/nhsn/ltc/weekly-covid-vac/index.html>

Data as of 1/24/2022 5:30 AM

Third Dose Improves Vaccine Effectiveness in Preventing COVID-19 Hospitalizations Among Immunocompetent and Immunocompromised Adults

TABLE 3. Effectiveness of 2-dose and 3-dose regimens of COVID-19 mRNA vaccines against COVID-19 hospitalization among adults with and without immunocompromising conditions — 21 hospitals, 18 U.S. states,*,† August–December 2021

Subgroup	Vaccinated versus unvaccinated, 2 doses		Vaccinated versus unvaccinated, 3 doses		P-value for VE comparison for 2-dose versus 3-dose recipients [§]
	No. vaccinated/ Total no. (%)	VE (95% CI)*	No. vaccinated/ Total no. (%)	VE (95% CI)*	
Patients without immunocompromising conditions					
COVID-19 case-patients	212/956 (22)	82 (77–86)	10/754 (1)	97 (95–99)	<0.001
Control patients	467/788 (59)		121/442 (27)		
Patients with immunocompromising conditions					
COVID-19 case-patients	196/383 (51)	69 (57–78)	36/223 (16)	88 (81–93)	<0.001
Control patients	376/513 (73)		145/282 (51)		

Abbreviation: VE = vaccine effectiveness.

Resources

- [CDC Interim Clinical Considerations for Use of COVID-19 Vaccines](#)
- [CDC COVID-19 Vaccines for Long-term Care Residents](#)
- [California COVID-19 Vaccine Eligibility Chart English | Spanish](#)
- [CDPH Comparison Guide of COVID-19 Vaccine Products](#)
- [CDPH Toolkit for LTCF Vaccination Resources](#)

Frequently Asked Questions (FAQs)

- [Frequently Asked Questions about COVID-19 Vaccination in Long-Term Care Facilities \(CDC\)](#)
- [FAQs about COVID-19 Boosters \(HHS\)](#)
- [Myths and Facts about the COVID-19 Vaccine \(CDC\)](#)
- [Community Toolkit for Addressing Health Misinformation \(HHS\)](#)